Oramed Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 15
- Market Cap
- $97.4M
- Introduction
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
Oramed Pharmaceuticals Invests $36.9 Million in Alpha Tau Medical to Advance Cancer Radiation Therapy
Oramed Pharmaceuticals has invested $36.9 million in Alpha Tau Medical, acquiring approximately 14.1 million shares and establishing a three-year strategic collaboration to accelerate Alpha DaRT cancer therapy development.
Oramed Pharmaceuticals Advances Oral Insulin Program with New Phase 3 Trial
Oramed Pharmaceuticals is set to initiate a Phase 3 trial of its oral insulin capsule, ORMD-0801, focusing on patient subpopulations that showed positive responses in prior studies.